Live feed08:36:19·22dANALYSTRatingvia QuantisnowGoldman resumed coverage on Neurocrine Biosciences with a new price targetByQuantisnow·Wall Street's wire, on your screen.NBIX· Neurocrine Biosciences Inc.Health CareOriginal source